Artielle ImmunoTherapeutics is pioneering a unique platform of biologic drugs aimed at treating a variety of inflammatory and degenerative diseases, with a primary focus on neuroinflammatory conditions such as multiple sclerosis (MS), optic neuritis, and stroke. The company’s innovative approach centers on targeting the CD74 receptor on monocytes, which plays a crucial role in modulating the immune response. By blocking the action of macrophage migration inhibitory factor (MIF), Artielle's therapies aim to reduce the recruitment of inflammatory cells to injury sites and promote apoptosis of these harmful mediators. This mechanism not only addresses the inflammatory response but also shows promise in neurodegenerative contexts, as the biologic molecules interact directly with microglial cells, which are implicated in neuroinflammation.

Artielle's lead clinical candidate, RTL1000, has demonstrated significant efficacy in preclinical models, particularly in reversing symptoms of MS and promoting the repair of myelin and axonal tissue. The platform leverages molecules derived from a portion of the MHC II molecule, which enhances both disease specificity and stability. Mechanistic studies indicate that RTL1000 can downregulate MIF activity, reduce the expression of adhesion molecules like ICAM-1, and shift cytokine profiles from pro-inflammatory to anti-inflammatory states. These findings suggest a robust therapeutic potential for Artielle's biologics in treating not only MS but also other autoimmune diseases, thereby addressing a critical need in the management of chronic inflammatory conditions.

United States

Artielle ImmunoTherapeutics

California - North

Artielle ImmunoTherapeutics

Company Details